Orlistat: a comprehensive review of a lipase inhibitor from obesity management to emerging oncological applications
Abstract
Orlistat, a potent inhibitor of gastric and pancreatic lipases, has been a cornerstone of pharmacological obesity management for over 2 decades. By reducing dietary fat absorption, it facilitates modest but clinically significant weight loss and helps prevent weight regain when combined with lifestyle interventions. Its use is associated with improvements in a range of obesity-related comorbidities, including enhanced glycemic control, reduced risk of type 2 diabetes progression, and favorable modifications of cardiovascular risk factors such as dyslipidemia. However, its clinical utility is often limited by predictable gastrointestinal adverse effects, which can impact patient adherence. Beyond its established role in weight control, a growing body of preclinical evidence has unveiled Orlistat's off-target activity as an inhibitor of fatty acid synthase (FASN), a key enzyme in de novo lipogenesis that is frequently overexpressed in various cancers. This discovery has spurred investigation into its potential as an anti-neoplastic agent, with studies demonstrating its ability to induce apoptosis, arrest cell cycle progression, and synergize with immunotherapy in cancer models. This review provides a comprehensive analysis of Orlistat, covering its molecular mechanisms, clinical efficacy and safety in diverse populations, impact on metabolic health, and the exciting, yet nascent, evidence for its repurposing in oncology.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.